TENX

Tenax Therapeutics, Inc. [TENX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TENX Stock Summary

Top 10 Correlated ETFs

TENX

Top 10 Correlated Stocks

TENX

In the News

TENX Financial details

Company Rating
-
Market Cap
7.36M
Income
-10.66M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-37.46
Forward P/E
-
PEG
4.15
P/S
-
P/B
33.11
P/C
-
P/FCF
-0.66
Quick Ratio
18.5
Current Ratio
19.73
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-58.86
EPS next Y
-
EPS next Q
-
EPS this Y
-94.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
63.54%
-
-
-
-
SMA20
-14.31%
SMA50
-14.31%
SMA100
12.37%
Inst Own
-
Inst Trans
-
ROA
-84%
ROE
-99%
ROC
-1.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.48-61.2
52W High
-91.57%
52W Low
+71.33%
RSI
32.01
Rel Volume
0.03
Avg Volume
361.07K
Volume
10.48K
Perf Week
-7.05%
Perf Month
-16.96%
Perf Quarter
7.53%
Perf Half Y
26.91%
-
-
-
-
Beta
2.267
-
-
Volatility
0.12%, 0.42%
Prev Close
-3.38%
Price
5.14
Change
-6.55%

Something similar

Top by Market Cap
BRYN.DE
VOO
GOOG
VFINX
BRK-A
Top Correlated ETFs
IGEA.SW
LYTR.DE
EM1C.DE
HY3M.DE
ZPDH.DE
Top Correlated Stocks
BMY
SEC.TO
BRM.DE
4AB.DE
CREO.L
Similar Market Cap
BRST
IFBD
JJM
AEHL
JNHA.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 361.07K
  • Market Capitalization 7.36M
  • Employee 5
  • CEO Mr. Christopher T. Giordano
  • Headquarters Morrisville,NC,US
  • IPO Date 1994-04-04
  • Website https://www.tenaxthera.com

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.